Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
1.430
+0.031 (2.22%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Theriva Biologics Employees
Theriva Biologics had 22 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
22
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,166,045
Market Cap
3.98M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
TOVX News
- 13 days ago - Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - GlobeNewsWire
- 5 weeks ago - Theriva™ Biologics to Present at the 2025 NeauxCancer Conference - GlobeNewsWire
- 6 weeks ago - Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results - GlobeNewsWire
- 7 weeks ago - Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual - GlobeNewsWire
- 4 months ago - Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 6 months ago - Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - GlobeNewsWire
- 7 months ago - Theriva Biologics Announces Pricing of $2.5 Million Public Offering - GlobeNewsWire
- 7 months ago - Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire